Abstract: This application describes a family of compounds acting as ?-arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases.
Abstract: Formulations having anti-adherent properties are disclosed herein. The anti-adherent formulation described herein acts to prevent the adherence of menses and/or fecal material to the skin in the labial and perianal regions during and after menstruation or defecation, respectively. The anti-adherent formulation contains a carrier, from about 0.1% by weight to about 10.0% by weight of a quaternary ammonium compound, and from about 0.5% by weight to about 10.0% by weight of a fatty alcohol. The anti-adherent formulation may be applied to the targeted surface either directly, in liquid form, such as by a spray bottle or similar packaging capable of delivering a liquid formulation in a relatively uniform amount over the full surface to be covered. Alternatively, the formulation may be applied to the targeted surface by a “wet” wipe or wiper.
Type:
Grant
Filed:
April 30, 2012
Date of Patent:
July 9, 2013
Inventors:
Uyen T. Lam, Kelly Laura Wolff, Corey T. Cunningham, Douglas R. Hoffman, Scott W. Wenzel
Abstract: The present invention provides compositions and methods for research, diagnostic, drug screening, and therapeutic applications related to paroxysmal dystonic choreoathetosis and related conditions. In particular, the present invention provides mutations in the myofibrillogenesis regulator 1 (MR-1) gene associated with such conditions.
Type:
Grant
Filed:
March 23, 2010
Date of Patent:
July 9, 2013
Assignee:
The Regents of the University of Michigan
Abstract: Disclosed here is a method for measuring the kinetics (i.e., the molecular flux rates—synthesis and breakdown or removal rates) of a plurality of proteins or organic metabolites in living systems. The methods may be accomplished in a high-throughput, large-scale automated manner, by using existing mass spectrometric profiling techniques and art well known in the fields of static proteomics and static organeomics, without the need for additional biochemical preparative steps or analytic/instrumental devices.
Type:
Grant
Filed:
March 1, 2012
Date of Patent:
July 9, 2013
Assignee:
The Regents of the University of California
Abstract: The invention concerns Au(III) complexes of the type [AuIIIX2(Pdtc)] (X=halogen, pseudo-halogen; pdtc=peptide-/esterified peptidedithiocarbamato) which are able to both maintain the antitumor properties and the lack of nephrotoxic side-effects of the previously reported Au(III)-dithiocarbamato complexes, together with an improved bioavailability through the peptide-mediated cellular internalization. The Au(III) complexes described have shown a significant biological activity on human tumor cell lines and, thus, they can be advantageously used as antineoplastic agents. The preparation method and use for the treatment of tumor pathologies of the Au(III) complexes of the invention are further described.
Type:
Grant
Filed:
March 20, 2009
Date of Patent:
July 9, 2013
Assignees:
Universita' Degli Studi di Padova, Centro di Riferimento Oncologico, Wayne State University Board of Govenors
Abstract: Embodiments described herein are directed to methods for the treatment and control of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and in delaying the onset of or reducing the risk of conditions and sequelae that are associated with these diseases, including atherosclerosis and non-insulin dependent diabetes. In addition, embodiments are directed to methods of treating coronary heart disease and metabolic syndrome. Embodiments are also directed to neurotensin analogs. In embodiments, the neurotensin analogs may be capable of binding to neurotensin receptors and, upon binding, may modulate the levels of lipids in subjects.
Abstract: Sequence-specific polymers are proving to be a powerful approach to assembly and manipulation of matter on the nanometer scale. Ligands that are peptoids, or sequence-specific N-functional glycine oligomers, allow precise and flexible control over the arrangement of binding groups, steric spacers, charge, and other functionality. We have synthesized short peptoids that can prevent the aggregation of gold nanoparticles in high-salt environments including divalent salt, and allow co-adsorption of a single DNA molecule. This degree of precision and versatility is likely to prove essential in bottom-up assembly of nanostructures and in biomedical applications of nanomaterials.
Type:
Grant
Filed:
January 12, 2011
Date of Patent:
June 11, 2013
Assignee:
Sandia Corporation
Inventors:
David Bruce Robinson, Ronald Zuckermann, George M. Buffleben
Abstract: The present invention provides compounds of Formula (I) that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase.
Type:
Grant
Filed:
March 10, 2010
Date of Patent:
June 4, 2013
Assignee:
Pfizer Inc.
Inventors:
Jeffrey Allen Pfefferkorn, Anthony Lai Ling
Abstract: The present invention is an inhibitor of the trypsin-like ?2/?2i sites of the proteasome. The inhibitor is characterized as being a peptide-based epoxyketone or vinyl sulfone that contains an arginine or 4-aminomethylene-L-phenylalanine at the C-terminus (i.e., at the P1 position). Methods for using the inhibitor to inhibit the activity of the ?2/?2i site of a proteasome and treat a proteasome-mediated disease or condition are also described.
Type:
Grant
Filed:
February 17, 2012
Date of Patent:
June 4, 2013
Assignees:
Trustees of Dartmout College, Leiden University
Inventors:
Alexei Kisselev, Dmitry V. Filippov, Herman Overkleeft
Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
Type:
Grant
Filed:
December 11, 2008
Date of Patent:
May 28, 2013
Assignee:
Tranzyme Pharma Inc.
Inventors:
Graeme L. Fraser, Hamid R. Hoveyda, Mark L. Peterson
Abstract: There are provided an anionic polymer, a polyion complex, and a ternary polymer composite, each of which is stable in a biological environment and is capable of realizing small RNA delivery without causing any undesired immune response. An anionic polymer according to an embodiment of the invention includes: a main chain which includes repeating units having carboxyl groups; and a side chain which is linked with part of the carboxyl groups in the main chain and is represented by the following formula: -A-B—X where: A represents a residue having one or more aminoethyl bonds; B represents an in vivo cleavable bond; and X represents a small RNA. A polyion complex according to an embodiment of the invention includes the anionic polymer as described above and a cationic polymer. A ternary polymer composite according to an embodiment of the invention includes the polyion complex as described above and a charge conversional polymer.
Abstract: The present invention provides an itch suppressant containing cholecystokinin 2 receptor agonist such as a peptide having an amino acid sequence homologous with a partial amino acid sequence of at least seven C-terminal amino acids of the peptide having the amino acid sequence represented by SEQ:ID No. 1 as an active ingredient as a rapid-acting itch suppressant effective in treating skin illnesses associated with strong itch such as atopic dermatitis having few side effects. [SEQ:?ID?No.
Type:
Grant
Filed:
October 22, 2010
Date of Patent:
May 21, 2013
Assignee:
University of Occupational and Environmental Health, Japan
Abstract: The invention relates to Fmoc (9-fluorenyl-methoxycarbonyl)-based polymeric conjugates. These conjugates are useful for extending the in-vivo circulation of protein and peptide drugs.
Type:
Grant
Filed:
January 15, 2010
Date of Patent:
May 21, 2013
Assignees:
Baxter International Inc., Baxter Healthcare SA
Abstract: Ligands having a metal binding domain and a targeting domain are provided. The ligands can be used to target, inhibit, and catalytically degrade or inactivate a desired target. Methods of treating a disease or condition using the ligands are also provided.
Type:
Grant
Filed:
June 1, 2005
Date of Patent:
May 21, 2013
Assignee:
The Ohio State University
Inventors:
James A. Cowan, Yan Jin, Seth Bradford, Nikhil Gokhale, Ada Cowan, Chun-An Chen
Abstract: The invention relates to nucleic acid molecules encoding peptides which are directed against autoantibodies associated with cold allergy, to the peptides themselves, to a pharmaceutical composition comprising said nucleic acid molecules and peptides, and to the use of said nucleic acid molecules and peptides for the treatment of circulatory disorders associated with exposure to cold or intolerance to cold, especially cold allergies.
Abstract: The present invention relates to a novel composition comprising an implant, scaffold or construct bound to a biological or chemical moiety. The bound moiety has the ability to bind to a component of the extracellular matrix of biological tissue, allowing the implant to be bound to the biological tissue in a short period of time after implantation. The invention also relates to the use and manufacture of this novel composition, as well as a novel use for the protein CNA.
Type:
Grant
Filed:
January 19, 2012
Date of Patent:
May 14, 2013
Assignees:
New York Society for the Ruptured and Crippled Maintaining the Hospital for Special Surgery, The Trustees of Princeton University, The Texas A&M University System
Inventors:
Suzanne A. Maher, Jeffrey Schwartz, Axel Oscar Magnus Hook, Brooke Hageman Russell, Casey Marie Jones
Abstract: Disclosed are peptide derivatives, wherein glutathione-like peptides are connected to benzoic acid derivatives, and a cosmetic composition comprising the same. The peptide derivatives have excellent tyrosinase inhibition and anti-oxidative activities to show excellent skin whitening effect, biocompatibility without skin stimulation, and stability during long-term storage. Therefore, they can be effectively used for a cosmetic composition for skin whitening.
Type:
Grant
Filed:
December 23, 2009
Date of Patent:
May 7, 2013
Assignee:
Bio-FD&C Co., Ltd
Inventors:
Dai Hyun Jung, Sang Hyun Moh, Jung Hun Lee, Su Jung Kim, Hyung Sik Kim, Hyo Hyun Seo, Yeon Ja Bae
Abstract: Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction in a newly discovered metabolic pathway. According to the normal functioning on this pathway, fructose-lysine-3-phosphate (FL3P) is broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins) Also disclosed are therapeutic methods of using such inhibitors to alleviate deleterious effects of 3DG.